Explore
Validate
LearnPA5-29015
antibody from Invitrogen Antibodies
Targeting: CCR6
BN-1, CD196, CKR-L3, CMKBR6, DCR2, DRY-6, GPR-CY4, GPR29, STRL22
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [2]
- Immunohistochemistry [2]
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-29015 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CCR6 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- Recommended positive controls: 293T, A431, H1299, HeLaS3, HepG2, Molt-4, Raji.
- Concentration
- 1 mg/mL
Submitted references Expression of CCL20 and Its Corresponding Receptor CCR6 Is Enhanced in Active Inflammatory Bowel Disease, and TLR3 Mediates CCL20 Expression in Colonic Epithelial Cells.
Skovdahl HK, Granlund Av, Østvik AE, Bruland T, Bakke I, Torp SH, Damås JK, Sandvik AK
PloS one 2015;10(11):e0141710
PloS one 2015;10(11):e0141710
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot using CCR6 Polyclonal Antibody (Product # PA5-29015). Sample (30 µg of whole cell lysate). A: HepG2. B: Molt-4. C: Raji. 12% SDS PAGE. CCR6 Polyclonal Antibody (Product # PA5-29015) diluted at 1:1,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot was performed using Anti-CCR6 Polyclonal Antibody (Product # PA5-29015) and a 43 kDa band corresponding to CCR6 was observed in the cell lines tested. Whole cell extracts (30 µg lysate) of HCT 116 (Lane 1), Caco-2 (Lane 2), HT-29 (Lane 3), SW480 (Lane 4), Jurkat (Lane 5), Raji (Lane 6), MOLT-4 (Lane 7) and HeLa (Lane 8) were electrophoresed using Novex® NuPAGE® 4-12 % Bis-Tris gel (Product # NP0321BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blots were probed with the primary antibody (1:1000 dilution) and detected by chemiluminescence with Goat anti-Rabbit IgG (H+L), Superclonal™ Recombinant Secondary Antibody, HRP conjugate (Product # A27036, 1:4000 dilution) using the iBright FL 1000 (Product # A32752). Chemiluminescent detection was performed using Novex® ECL Chemiluminescent Substrate Reagent Kit (Product # WP20005).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- CCR6 Polyclonal Antibody detects CCR6 protein at membrane on human hepatoma by immunohistochemical analysis. Sample: Paraffin-embedded hepatoma. CCR6 Polyclonal Antibody (Product # PA5-29015) dilution: 1:1,000. Antigen Retrieval: EDTA based buffer, pH 8.0, 15 min.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of paraffin-embedded DU-145 xenograft, using CCR6 (Product # PA5-29015) antibody at 1:100 dilution. Antigen Retrieval: EDTA based buffer, pH 8.0, 15 min.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 5 CCR6 protein and mRNA in serial sections. Immunohistochemistry (IHC) and in situ hybridization (ISH) show CCR6 protein and mRNA in colonic biopsies from active UC and inactive CD. Serial sections from the same biopsy were used to compare the localization of mRNA and protein. Arrows show that there is no overlap of protein and mRNA in active disease (a, b), while a clear overlap is seen in inactive disease(c). Scale bars as indicated.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig 6 Immune cell typing of CCL20 and CCR6 positive cells in serial sections. Immunohistochemistry on serial sections from the same biopsy was performed to localize CCR6 and CCL20 positivity to different immune cells. A: Sections from biopsies from active disease were used for CCL20 investigations. There is a partial overlap between CCL20+ cells and CD3+, CD45RO+ and CD20+ cells (arrows a, b, c, d). B: Sections from biopsies from inactive disease for CCR6. There is a partial overlap between CCR6+ cells and CD1alpha+ cells (arrows a, b). Scale bars as indicated.
